NNC6019-0001 is named as an intervention in 2 current clinical trials in our USA, Ireland, UK and China registers. 1 is recruiting patients now. The most common phase is Phase 3. The lead sponsor is Novo Nordisk A/S. The most-studied condition is Transthyretin Amyloid Cardiomyopathy (ATTR CM).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811 · Transthyretin Amyloid Cardiomyopathy (ATTR CM)
|
Phase 3 | Recruiting | Novo Nordisk A/S | Ireland, UK, USA, China |
|
A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis
NCT06260709 · ClinicalTrials.gov ↗ · Transthyretin Amyloid Cardiomyopathy (ATTR CM)
|
Phase 2 | Active, closed | Novo Nordisk A/S | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Novo Nordisk A/S | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 1 |
| Clinical trials in Ireland | 1 | 1 |
| Clinical trials in UK | 1 | 1 |
| Clinical trials in China | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA, Ireland, UK and China registers name NNC6019-0001 as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in USA, 1 with sites in Ireland, 1 with sites in UK and 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Novo Nordisk A/S. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how NNC6019-0001 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how NNC6019-0001 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists NNC6019-0001 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.